Tolerability and effectiveness of preservative-free dorzolamide&ndash;timolol (preservative-free Cosopt&reg;) in patients with open-angle glaucoma or ocular hypertension

Código QR

Tolerability and effectiveness of preservative-free dorzolamide&ndash;timolol (preservative-free Cosopt&reg;) in patients with open-angle glaucoma or ocular hypertension

Cindy Hutnik1, David Neima2, Fahim Ibrahim3, Robert Scott4, Julie Vaillancourt5, Denis Haine5, John S Sampalis5, Natacha Bastien6, Sylvain Foucart61Ivey Eye Institute, St Joseph Healthcare, London, Ontario, Canada; 2New Westminster, British Columbia, Canada; 3Point Edward, Ontario, Canada; 4Kentvill...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cindy Hutnik, David Neima, Fahim Ibrahim, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/95281ebdbef64e6db5b2468917e524bf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

A patient preference comparison of Azarga&trade; (brinzolamide/timolol fixed combination) vs Cosopt&reg; (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension
por: Thomas K Mundorf, et al.
Publicado: (2008)

Patient perspectives when switching from Cosopt&reg; (dorzolamide-timolol) to Azarga&trade; (brinzolamide-timolol) for glaucoma requiring multiple drug therapy
por: Auger GA, et al.
Publicado: (2012)

Efficacy and safety of travoprost/timolol vs dorzolamide/timolol in patients with open-angle glaucoma or ocular hypertension
por: Miguel A Teus, et al.
Publicado: (2009)

Rational use of the fixed combination of dorzolamide &ndash; timolol in the management of raised intraocular pressure and glaucoma
por: Jason Yeh, et al.
Publicado: (2008)

Preference for a fixed combination of brinzolamide/timolol versus dorzolamide/ timolol among patients with open-angle glaucoma or ocular hypertension
por: Sanseau A, et al.
Publicado: (2013)

Brinzolamide 1%/timolol versus dorzolamide 2%/timolol in the treatment of open-angle glaucoma or ocular hypertension: prospective randomized patient-preference study
por: Altafini R, et al.
Publicado: (2015)

Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study
por: Pillunat LE, et al.
Publicado: (2017)

Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension
por: Lanzl I, et al.
Publicado: (2013)

Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice
por: Pillunat LE, et al.
Publicado: (2016)

Glaucoma therapy: preservative-free for all?
por: Thygesen J
Publicado: (2018)

Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice
por: Pfennigsdorf S, et al.
Publicado: (2016)

Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops
por: Rosin LM, et al.
Publicado: (2013)

Preliminary results following the use of a fixed combination of timolol&ndash;brimonidine in patients with ocular hypertension and primary open-angle glaucoma
por: Dimitris Papaconstantinou, et al.
Publicado: (2009)

Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma
por: Ermiş&nbsp;SS
Publicado: (2012)

Intraocular pressure reduction of fixed combination timolol maleate 0.5% and dorzolamide 2% (Cosopt) administered three times a day
por: Moisseiev E,&nbsp;Lazar M, et al.
Publicado: (2012)

Comparison of ocular surface assessment and adherence between preserved and preservative-free latanoprost in glaucoma: a parallel-grouped randomized trial
por: Dai Woo Kim, et al.
Publicado: (2021)

Efficacy and safety of benzalkonium chloride-free fixed-dose combination of latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension
por: Bhagat P, et al.
Publicado: (2014)

Effect of dorzolamide/timolol combination on the visual field in glaucoma
por: Takeda S, et al.
Publicado: (2014)

Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost
por: Gregory Katz, et al.
Publicado: (2010)

Comparison of timolol 0.5% + brimonidine 0.2% + dorzolamide 2% versus timolol 0.5% + brimonidine 0.2% in a Mexican population with primary open-angle glaucoma or ocular hypertension
por: Baiza-Dur&aacute;n LM, et al.
Publicado: (2012)

Treatment persistence and cost-effectiveness of latanoprost/latanoprost&ndash;timolol, bimatoprost/bimatoprost&ndash;timolol, and travoprost/travoprost&ndash;timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database
por: Antoine Lafuma, et al.
Publicado: (2011)

Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study
por: Economou MA, et al.
Publicado: (2018)

Safety, tolerability, and efficacy of fixed combination therapy with dorzolamide hydrochloride 2% and timolol maleate 0.5% in glaucoma and ocular hypertension
por: Nicholas P Bell, et al.
Publicado: (2010)

Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
por: Ruangvaravate N, et al.
Publicado: (2020)

Assessment of dry eye signs and symptoms and ocular tolerance of a preservative-free lacrimal substitute (Hylabak®) versus a preserved lacrimal substitute (Systane®) used for 3 months in patients after LASIK
por: Astakhov YS, et al.
Publicado: (2013)

Ocular hypotensive effect, preservation of visual fields, and safety of adding dorzolamide to prostaglandin therapy for twelve months
por: Kenji Inoue, et al.
Publicado: (2011)

Efficacy and safety of brinzolamide/timolol fixed combination compared with timolol in Japanese patients with open-angle glaucoma or ocular hypertension
por: Yoshikawa K, et al.
Publicado: (2014)

Safety and efficacy of fixed-combination travoprost/timolol in patients with open-angle glaucoma or ocular hypertension not controlled with timolol monotherapy
por: Jordão MLS, et al.
Publicado: (2014)

Efficacy and safety of brinzolamide/timolol fixed combination compared with timolol in Japanese patients with open-angle glaucoma or ocular hypertension [Erratum]
por: Yoshikawa K, et al.
Publicado: (2014)

Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma
por: Janulevičienė I, et al.
Publicado: (2012)

Efficacy and tolerability of preservative-free tafluprost 0.0015% in Korean patients with glaucoma
por: Hwang YH
Publicado: (2013)

An observational study of bimatoprost 0.01% in treatment-na&iuml;ve patients with primary open angle glaucoma or ocular hypertension: the CLEAR trial
por: Nixon DR, et al.
Publicado: (2012)

Update and optimal use of a brinzolamide-timolol fixed combination in open-angle glaucoma and ocular hypertension
por: Syed MF, et al.
Publicado: (2011)

Efficacy of preservative-free tafluprost in patients with normal-tension glaucoma previously treated with latanoprost
por: Sacchi M, et al.
Publicado: (2014)

Systane&reg; lubricant eye drops in the management of ocular dryness
por: Benelli U
Publicado: (2011)

Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost
por: Hommer A, et al.
Publicado: (2011)

Fixed combination of bimatoprost and timolol in patients with primary open-angle glaucoma or ocular hypertension with inadequate IOP adjustment
por: Gerrett Brief, et al.
Publicado: (2010)

Bevacizumab (Avastin&reg;) for the management of anterior chamber neovascularization and neovascular glaucoma
por: Dimitrios Brouzas, et al.
Publicado: (2009)

Efficacy and patient tolerability of travoprost BAK-free solution in patients with open-angle glaucoma and ocular hypertension
por: Sophia K Mirza, et al.
Publicado: (2010)

Use of preservative-free hyaluronic acid (Hylabak®) for a range of patients with dry eye syndrome: experience in Russia
por: Brzhesky VV, et al.
Publicado: (2014)